Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 318 articles:
HTML format



Single Articles


    January 2022
  1. MASCIA F, Mazo I, Alterovitz WL, Karagiannis K, et al
    In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines.
    PLoS One. 2022;17:e0262134.
    PubMed     Abstract available


  2. MOHAMED EA, Rashed EA, Gaber T, Karam O, et al
    Deep learning model for fully automated breast cancer detection system from thermograms.
    PLoS One. 2022;17:e0262349.
    PubMed     Abstract available


  3. HUTAJULU SH, Prabandari YS, Bintoro BS, Wiranata JA, et al
    Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study.
    PLoS One. 2022;17:e0262468.
    PubMed     Abstract available


  4. ZAHRAN AM, Rayan A, Zahran ZAM, Mohamed WMY, et al
    Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
    PLoS One. 2022;17:e0262650.
    PubMed     Abstract available


  5. HOZHABRI H, Ghasemi Dehkohneh RS, Razavi SM, Razavi SM, et al
    Comparative analysis of protein-protein interaction networks in metastatic breast cancer.
    PLoS One. 2022;17:e0260584.
    PubMed     Abstract available


  6. SILVA DAS
    Hospitalization and ambulatory costs related to breast cancer due to physical inactivity in the Brazilian state capitals.
    PLoS One. 2022;17:e0261019.
    PubMed     Abstract available


  7. CAO X, Li Y, Wang Y, Yu T, et al
    Curcumin suppresses tumorigenesis by ferroptosis in breast cancer.
    PLoS One. 2022;17:e0261370.
    PubMed     Abstract available


  8. MURAYAMA MA, Takada E, Takai K, Arimitsu N, et al
    Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells.
    PLoS One. 2022;17:e0260838.
    PubMed     Abstract available


  9. TOMAS RC, Sayat AJ, Atienza AN, Danganan JL, et al
    Detection of breast cancer by ATR-FTIR spectroscopy using artificial neural networks.
    PLoS One. 2022;17:e0262489.
    PubMed     Abstract available


  10. SHI D, Li H, Zhang Z, He Y, et al
    Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway.
    PLoS One. 2022;17:e0262389.
    PubMed     Abstract available


  11. HUSSAIN I, Majeed A, Masood I, Ashraf W, et al
    A national survey to assess breast cancer awareness among the female university students of Pakistan.
    PLoS One. 2022;17:e0262030.
    PubMed     Abstract available


  12. RAJAGOPAL T, Seshachalam A, Rathnam KK, Talluri S, et al
    Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women.
    PLoS One. 2022;17:e0259761.
    PubMed     Abstract available


  13. LAZA-VASQUEZ C, Codern-Bove N, Cardona-Cardona A, Hernandez-Leal MJ, et al
    Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group study.
    PLoS One. 2022;17:e0263788.
    PubMed     Abstract available


  14. TSUI TCO, Trudeau M, Mitsakakis N, Torres S, et al
    Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions.
    PLoS One. 2022;17:e0262635.
    PubMed     Abstract available


  15. MARQUES AD, Moura AR, Hora EC, Brito EAC, et al
    Analysis of breast cancer survival in a northeastern Brazilian state based on prognostic factors: A retrospective cohort study.
    PLoS One. 2022;17:e0263222.
    PubMed     Abstract available


  16. HESARI E, Ahmadinezhad M, Arshadi M, Azizi H, et al
    The association between migraine and breast cancer risk: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263628.
    PubMed     Abstract available


  17. TSCHODU D, Ulm B, Bendrat K, Lippoldt J, et al
    Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature.
    PLoS One. 2022;17:e0261035.
    PubMed     Abstract available


  18. AKOKO LO, Rutashobya AK, Lutainulwa EW, Mwanga AH, et al
    The effect of reproductive, hormonal, nutritional and lifestyle on breast cancer risk among black Tanzanian women: A case control study.
    PLoS One. 2022;17:e0263374.
    PubMed     Abstract available


  19. KILBAS PO, Can ND, Kizilboga T, Ezberci F, et al
    CRISPR/Cas9-mediated Bag-1 knockout increased mesenchymal characteristics of MCF-7 cells via Akt hyperactivation-mediated actin cytoskeleton remodeling.
    PLoS One. 2022;17:e0261062.
    PubMed     Abstract available


  20. LV Z, Zhang W, Zhang Y, Zhong G, et al
    Metastasis patterns and prognosis of octogenarians with metastatic breast cancer: A large-cohort retrospective study.
    PLoS One. 2022;17:e0263104.
    PubMed     Abstract available


  21. PADMANABHAN H, Hassan NT, Wong SW, Lee YQ, et al
    Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.
    PLoS One. 2022;17:e0263675.
    PubMed     Abstract available


  22. CONTE F, Sibilio P, Grimaldi AM, Salvatore M, et al
    In silico recognition of a prognostic signature in basal-like breast cancer patients.
    PLoS One. 2022;17:e0264024.
    PubMed     Abstract available


  23. MARKELLOS C, Ourailidou ME, Gavriatopoulou M, Halvatsiotis P, et al
    Olive oil intake and cancer risk: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0261649.
    PubMed     Abstract available


  24. NELSON DR, Brown J, Morikawa A, Method M, et al
    Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
    PLoS One. 2022;17:e0264637.
    PubMed     Abstract available


  25. TSAI CJ, Huang HY, Chen FM, Yang YH, et al
    Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.
    PLoS One. 2022;17:e0262934.
    PubMed     Abstract available


  26. MAHMOOD T, Li J, Pei Y, Akhtar F, et al
    Breast lesions classifications of mammographic images using a deep convolutional neural network-based approach.
    PLoS One. 2022;17:e0263126.
    PubMed     Abstract available


  27. KWON D, Ko BK, Jung SP, Kim HK, et al
    Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    PLoS One. 2022;17:e0262709.
    PubMed     Abstract available


  28. TROUGHTON LD, O'Loughlin DA, Zech T, Hamill KJ, et al
    Laminin N-terminus alpha31 is upregulated in invasive ductal breast cancer and changes the mode of tumour invasion.
    PLoS One. 2022;17:e0264430.
    PubMed     Abstract available


  29. KOLODZIEJ M, Kaznowska E, Paszek S, Cebulski J, et al
    Characterisation of breast cancer molecular signature and treatment assessment with vibrational spectroscopy and chemometric approach.
    PLoS One. 2022;17:e0264347.
    PubMed     Abstract available


  30. KIM H, Lee SB, Kim J, Chung IY, et al
    Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study.
    PLoS One. 2022;17:e0265533.
    PubMed     Abstract available


  31. XU X, Soulos PR, Herrin J, Wang SY, et al
    Perioperative magnetic resonance imaging in breast cancer care: Distinct adoption trajectories among physician patient-sharing networks.
    PLoS One. 2022;17:e0265188.
    PubMed     Abstract available


  32. SHI SC, Zhang Y, Wang T
    High RRM2 expression has poor prognosis in specific types of breast cancer.
    PLoS One. 2022;17:e0265195.
    PubMed     Abstract available


  33. ZHU J, Oh JH, Deasy JO, Tannenbaum AR, et al
    vWCluster: Vector-valued optimal transport for network based clustering using multi-omics data in breast cancer.
    PLoS One. 2022;17:e0265150.
    PubMed     Abstract available


  34. BOUJEMAA M, Mighri N, Chouchane L, Boubaker MS, et al
    Health influenced by genetics: A first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population.
    PLoS One. 2022;17:e0265638.
    PubMed     Abstract available


  35. LIU J, Ho PJ, Tan THL, Yeoh YS, et al
    BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme.
    PLoS One. 2022;17:e0265965.
    PubMed     Abstract available


  36. BOMMI-REDDY A, Park-Chouinard S, Mayhew DN, Terzo E, et al
    CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
    PLoS One. 2022;17:e0262378.
    PubMed     Abstract available


  37. CHUAYCHAI A, Sriplung H
    A rapid rise in hormone receptor-positive and HER2-positive breast cancer subtypes in Southern Thai women: A population-based study in Songkhla.
    PLoS One. 2022;17:e0265417.
    PubMed     Abstract available


  38. ULLAH F, Khurshid N, Fatimi Q, Loidl P, et al
    Mutations in the acetylation hotspots of Rbl2 are associated with increased risk of breast cancer.
    PLoS One. 2022;17:e0266196.
    PubMed     Abstract available


  39. FLORES-GARCIA LC, Ventura-Gallegos JL, Romero-Cordoba SL, Hernandez-Juarez AJ, et al
    Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.
    PLoS One. 2022;17:e0266073.
    PubMed     Abstract available


  40. PETROCCHI S, Ongaro G, Calvello M, Feroce I, et al
    A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    PLoS One. 2022;17:e0266327.
    PubMed     Abstract available


  41. FILIPOWICZ N, Drezek K, Horbacz M, Wojdak A, et al
    Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition.
    PLoS One. 2022;17:e0266111.
    PubMed     Abstract available


  42. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    PubMed     Abstract available


  43. CHEN PC, Lee YC, Su YC, Lee CH, et al
    Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.
    PLoS One. 2022;17:e0266960.
    PubMed     Abstract available


  44. PEREZ CS, Mestriner C, Ribeiro LTN, Grillo FW, et al
    Relationship between lymphedema after breast cancer treatment and biophysical characteristics of the affected tissue.
    PLoS One. 2022;17:e0264160.
    PubMed     Abstract available


  45. SQUARA PA, Luu VP, Perol D, Coudert B, et al
    Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
    PLoS One. 2022;17:e0267242.
    PubMed     Abstract available


  46. HU H, Qiao S, Hao Y, Bai Y, et al
    Breast cancer histopathological images recognition based on two-stage nuclei segmentation strategy.
    PLoS One. 2022;17:e0266973.
    PubMed     Abstract available


  47. NUNEZ-RUIZ A, Sanchez-Brena F, Lopez-Pacheco C, Acevedo-Dominguez NA, et al
    Obesity modulates the immune macroenvironment associated with breast cancer development.
    PLoS One. 2022;17:e0266827.
    PubMed     Abstract available


  48. AI H
    GSEA-SDBE: A gene selection method for breast cancer classification based on GSEA and analyzing differences in performance metrics.
    PLoS One. 2022;17:e0263171.
    PubMed     Abstract available


  49. DAILY A, Ravishankar P, Harms S, Klimberg VS, et al
    Using tears as a non-invasive source for early detection of breast cancer.
    PLoS One. 2022;17:e0267676.
    PubMed     Abstract available


  50. TZELVES L, Manolitsis I, Varkarakis I, Ivanovic M, et al
    Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.
    PLoS One. 2022;17:e0265127.
    PubMed     Abstract available


  51. PARK SY, Kim JH, Chang JH, Park JM, et al
    Quantitative evaluation of radiodermatitis following whole-breast radiotherapy with various color space models: A feasibility study.
    PLoS One. 2022;17:e0264925.
    PubMed     Abstract available


  52. ARORA I, Sharma M, Li S, Crowley M, et al
    An integrated analysis of the effects of maternal broccoli sprouts exposure on transcriptome and methylome in prevention of offspring mammary cancer.
    PLoS One. 2022;17:e0264858.
    PubMed     Abstract available


  53. LOPEZ-JIMENEZ T, Duarte-Salles T, Plana-Ripoll O, Recalde M, et al
    Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.
    PLoS One. 2022;17:e0264634.
    PubMed     Abstract available


  54. HAO Y, Zhang L, Qiao S, Bai Y, et al
    Breast cancer histopathological images classification based on deep semantic features and gray level co-occurrence matrix.
    PLoS One. 2022;17:e0267955.
    PubMed     Abstract available


  55. KOYAMA K, Ishikawa H, Abe M, Shiose Y, et al
    Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
    PLoS One. 2022;17:e0267027.
    PubMed     Abstract available


  56. LI T, Li Y, Yang Y, Li J, et al
    Logistic regression analysis of ultrasound findings in predicting the malignant and benign phyllodes tumor of breast.
    PLoS One. 2022;17:e0265952.
    PubMed     Abstract available


  57. UEDA D, Yamamoto A, Onoda N, Takashima T, et al
    Development and validation of a deep learning model for detection of breast cancers in mammography from multi-institutional datasets.
    PLoS One. 2022;17:e0265751.
    PubMed     Abstract available


  58. OSE N, Takeuchi Y, Sakamaki Y, Kadota Y, et al
    Detection of lymph node metastasis in non-small cell lung cancer using the new system of one-step nucleic acid amplification assay.
    PLoS One. 2022;17:e0265603.
    PubMed     Abstract available


  59. ANNONI AM, Longhini C
    Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    PLoS One. 2022;17:e0265387.
    PubMed     Abstract available


  60. TAGHIZADEH MS, Niazi A, Moghadam A, Afsharifar A, et al
    Experimental, molecular docking and molecular dynamic studies of natural products targeting overexpressed receptors in breast cancer.
    PLoS One. 2022;17:e0267961.
    PubMed     Abstract available


  61. DAMASCENO KA, Santos-Conceicao AMD, Silva LP, Cardoso TMS, et al
    Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma.
    PLoS One. 2022;17:e0267648.
    PubMed     Abstract available


  62. SCHLIEMANN D, Hoe WMK, Mohan D, Allotey P, et al
    Challenges and opportunities for breast cancer early detection among rural dwelling women in Segamat District, Malaysia: A qualitative study.
    PLoS One. 2022;17:e0267308.
    PubMed     Abstract available


  63. MEDINA HN, Callahan KE, Koru-Sengul T, Maheshwari S, et al
    Elevated breast cancer mortality among highly educated Asian American women.
    PLoS One. 2022;17:e0268617.
    PubMed     Abstract available


  64. MA L, Bian M, Gao H, Zhou Z, et al
    A novel 3-acyl isoquinolin-1(2H)-one induces G2 phase arrest, apoptosis and GSDME-dependent pyroptosis in breast cancer.
    PLoS One. 2022;17:e0268060.
    PubMed     Abstract available


  65. CHANGKUN Z, Bishwajit G, Ji L, Tang S, et al
    Sociodemographic correlates of cervix, breast and oral cancer screening among Indian women.
    PLoS One. 2022;17:e0265881.
    PubMed     Abstract available


  66. ALAM MS, Sultana A, Reza MS, Amanullah M, et al
    Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
    PLoS One. 2022;17:e0268967.
    PubMed     Abstract available


  67. ZEMNI I, Kacem M, Dhouib W, Bennasrallah C, et al
    Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study.
    PLoS One. 2022;17:e0268035.
    PubMed     Abstract available


  68. GRANT E, Bucklain FA, Ginn L, Laity P, et al
    Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines.
    PLoS One. 2022;17:e0268300.
    PubMed     Abstract available


  69. ONAGA C, Tamori S, Matsuoka I, Ozaki A, et al
    High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer.
    PLoS One. 2022;17:e0268799.
    PubMed     Abstract available


  70. NGAN TT, Jenkins C, Minh HV, Donnelly M, et al
    Breast cancer screening practices among Vietnamese women and factors associated with clinical breast examination uptake.
    PLoS One. 2022;17:e0269228.
    PubMed     Abstract available


  71. TRAN T, Le U, Shi Y
    An effective up-sampling approach for breast cancer prediction with imbalanced data: A machine learning model-based comparative analysis.
    PLoS One. 2022;17:e0269135.
    PubMed     Abstract available


  72. NAM KH, Lee JH, Chung YS, Chun YS, et al
    The efficacy of oxidized regenerated cellulose (SurgiGuard(R)) in breast cancer patients who undergo total mastectomy with node surgery: A prospective randomized study in 94 patients.
    PLoS One. 2022;17:e0267694.
    PubMed     Abstract available


  73. MEURS CJC, Til JAV, Menke-Pluijmers MBE, Vet S, et al
    Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ.
    PLoS One. 2022;17:e0269551.
    PubMed     Abstract available


  74. TANDA N, Tada H, Washio J, Takahashi N, et al
    Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study.
    PLoS One. 2022;17:e0269335.
    PubMed     Abstract available


  75. XIA LY, Xu WY, Zhao Y
    Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer.
    PLoS One. 2022;17:e0270528.
    PubMed     Abstract available


  76. PUSPITANINGTYAS H, Sulistyoningrum DC, Witaningrum R, Widodo I, et al
    Vitamin D status in breast cancer cases following chemotherapy: A pre and post observational study in a tertiary hospital in Yogyakarta, Indonesia.
    PLoS One. 2022;17:e0270507.
    PubMed     Abstract available


  77. HARDEMAN AA, Han YJ, Grushko TA, Mueller J, et al
    Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.
    PLoS One. 2022;17:e0268693.
    PubMed     Abstract available


  78. SILVA DA COSTA N, Alves da Silva AS, de Melo-Neto JS
    Effects of dance therapy in women with breast cancer: A systematic review protocol.
    PLoS One. 2022;17:e0257948.
    PubMed     Abstract available


  79. PIEMONTESE A, Galvain T, Swindells L, Parago V, et al
    Budget impact analysis of HARMONIC FOCUS+ Shears for mastectomy and breast-conserving surgery with axillary lymph node dissection compared with monopolar electrocautery from an Italian hospital perspective.
    PLoS One. 2022;17:e0268708.
    PubMed     Abstract available


  80. PARK J, Kim C, Ki Y, Kim W, et al
    Incidence of hypothyroidism after treatment for breast cancer: A Korean population-based study.
    PLoS One. 2022;17:e0269893.
    PubMed     Abstract available


  81. MENG X, Wang L, He M, Yang Z, et al
    Cysteine conjugate beta-lyase 2 (CCBL2) expression as a prognostic marker of survival in breast cancer patients.
    PLoS One. 2022;17:e0269998.
    PubMed     Abstract available


  82. SARKER R, Islam MS, Moonajilin MS, Rahman M, et al
    Knowledge of breast cancer and breast self-examination practices and its barriers among university female students in Bangladesh: Findings from a cross-sectional study.
    PLoS One. 2022;17:e0270417.
    PubMed     Abstract available


  83. COX A, Martini A, Ghozlan H, Moroose R, et al
    Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.
    PLoS One. 2022;17:e0264651.
    PubMed     Abstract available


  84. REME SE, Munk A, Holter MTS, Falk RS, et al
    Pre- and post-operative psychological interventions to prevent pain and fatigue after breast cancer surgery (PREVENT): Protocol for a randomized controlled trial.
    PLoS One. 2022;17:e0268606.
    PubMed     Abstract available


  85. MELLOR P, Kendall S, Smith S, Saxena A, et al
    Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis.
    PLoS One. 2022;17:e0271090.
    PubMed     Abstract available


  86. CZUBAK-PROWIZOR K, Macieja A, Poplawski T, Zbikowska HM, et al
    Responses of human colon and breast adenocarcinoma cell lines (LoVo, MCF7) and non-tumorigenic mammary epithelial cells (MCF-10A) to the acellular fraction of packed red blood cells in the presence and absence of cisplatin.
    PLoS One. 2022;17:e0271193.
    PubMed     Abstract available


  87. MESSIER TL, Boyd JR, Gordon JAR, Tye CE, et al
    Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells.
    PLoS One. 2022;17:e0271725.
    PubMed     Abstract available


  88. CONTI B, Bochaton A, Charreire H, Kitzis-Bonsang H, et al
    Influence of geographic access and socioeconomic characteristics on breast cancer outcomes: A systematic review.
    PLoS One. 2022;17:e0271319.
    PubMed     Abstract available


  89. DIOSAN L, Andreica A, Voiculescu I
    On the use of multi-objective evolutionary classifiers for breast cancer detection.
    PLoS One. 2022;17:e0269950.
    PubMed     Abstract available


  90. YANG Z, Liu J, Wang Q
    Diagnose earlier, live longer? The impact of cervical and breast cancer screening on life span.
    PLoS One. 2022;17:e0270347.
    PubMed     Abstract available


  91. ACEA-NEBRIL B, Garcia-Novoa A, Garcia Jimenez L
    The PreQ-20 TRIAL: A prospective cohort study of the oncologic safety, quality of life and cosmetic outcomes of patients undergoing prepectoral breast reconstruction.
    PLoS One. 2022;17:e0269426.
    PubMed     Abstract available


  92. FUNGA ML, Dilebo ZD, Shuramo AG, Bereku T, et al
    Assessing breast cancer awareness on reproductive age women in West Badewacho Woreda, Hadiyya Zone, South Ethiopia; Community based cross- sectional study.
    PLoS One. 2022;17:e0270248.
    PubMed     Abstract available


  93. CHEN CC, Ho WL, Lin CH, Chen HH, et al
    Stratified analysis of the association between periodontitis and female breast cancer based on age, comorbidities and level of urbanization: A population-based nested case-control study.
    PLoS One. 2022;17:e0271948.
    PubMed     Abstract available


  94. DEY M, Rana SP, Loretoni R, Duranti M, et al
    Automated breast lesion localisation in microwave imaging employing simplified pulse coupled neural network.
    PLoS One. 2022;17:e0271377.
    PubMed     Abstract available


  95. WANG J, Chen X, Wang L, Zhang C, et al
    Does aquatic physical therapy affect the rehabilitation of breast cancer in women? A systematic review and meta-analysis of randomized controlled trials.
    PLoS One. 2022;17:e0272337.
    PubMed     Abstract available


  96. KHAJAH MA, Khushaish S, Luqmani YA
    Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro.
    PLoS One. 2022;17:e0272449.
    PubMed     Abstract available


  97. LAZAR IM, Karcini A, Haueis JRS
    Mapping the cell-membrane proteome of the SKBR3/HER2+ cell line to the cancer hallmarks.
    PLoS One. 2022;17:e0272384.
    PubMed     Abstract available


    January 2021
  98. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    PubMed     Abstract available


  99. GALILI B, Tekpli X, Kristensen VN, Yakhini Z, et al
    Efficient gene expression signature for a breast cancer immuno-subtype.
    PLoS One. 2021;16:e0245215.
    PubMed     Abstract available


  100. BHANDARI D, Shibanuma A, Kiriya J, Hirachan S, et al
    Factors associated with breast cancer screening intention in Kathmandu Valley, Nepal.
    PLoS One. 2021;16:e0245856.
    PubMed     Abstract available


  101. ALLMAN R, Spaeth E, Lai J, Gross SJ, et al
    A streamlined model for use in clinical breast cancer risk assessment maintains predictive power and is further improved with inclusion of a polygenic risk score.
    PLoS One. 2021;16:e0245375.
    PubMed     Abstract available


  102. SAFI N, Saunders C, Hayen A, Anazodo A, et al
    Gestational breast cancer in New South Wales: A population-based linkage study of incidence, management, and outcomes.
    PLoS One. 2021;16:e0245493.
    PubMed     Abstract available


  103. ELLINGJORD-DALE M, Papadimitriou N, Katsoulis M, Yee C, et al
    Coffee consumption and risk of breast cancer: A Mendelian randomization study.
    PLoS One. 2021;16:e0236904.
    PubMed     Abstract available


  104. SALGUERO-ARANDA C, Sancho-Mensat D, Canals-Lorente B, Sultan S, et al
    Expression of Concern: STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines.
    PLoS One. 2021;16:e0246415.
    PubMed    


  105. NIEF C, Morhard R, Chelales E, Adrianzen Alvarez D, et al
    Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model.
    PLoS One. 2021;16:e0234535.
    PubMed     Abstract available


  106. BOUJEMAA M, Hamdi Y, Mejri N, Romdhane L, et al
    Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.
    PLoS One. 2021;16:e0245362.
    PubMed     Abstract available


  107. CHIN CH, Tseng LM, Chao TC, Wang TJ, et al
    Self-care as a mediator between symptom-management self-efficacy and quality of life in women with breast cancer.
    PLoS One. 2021;16:e0246430.
    PubMed     Abstract available


  108. XU S, Wang H, Liu Y, Zhang C, et al
    Hair chemicals may increase breast cancer risk: A meta-analysis of 210319 subjects from 14 studies.
    PLoS One. 2021;16:e0243792.
    PubMed     Abstract available


  109. OLIVEIRA NPD, Cancela MC, Martins LFL, de Souza DLB, et al
    Spatial distribution of advanced stage diagnosis and mortality of breast cancer: Socioeconomic and health service offer inequalities in Brazil.
    PLoS One. 2021;16:e0246333.
    PubMed     Abstract available


  110. ZHOU Y, Yuan Y, Li L, Wang X, et al
    HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer.
    PLoS One. 2021;16:e0245832.
    PubMed     Abstract available


  111. HONG JH, Goo JM, Moon HG, Chang JM, et al
    Usefulness of staging chest-CT in patients with operable breast cancer.
    PLoS One. 2021;16:e0246563.
    PubMed     Abstract available


  112. BAR H, Bang S
    A mixture model to detect edges in sparse co-expression graphs with an application for comparing breast cancer subtypes.
    PLoS One. 2021;16:e0246945.
    PubMed     Abstract available


  113. ZHANG H, Zhang LQ, Yang CC, Li J, et al
    The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling.
    PLoS One. 2021;16:e0245876.
    PubMed     Abstract available


  114. SCIMONE MT, Krishnamurthy S, Maguluri G, Preda D, et al
    Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.
    PLoS One. 2021;16:e0245334.
    PubMed     Abstract available


  115. YANAI H, Yoshikawa K, Ishida M, Tsuta K, et al
    Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study.
    PLoS One. 2021;16:e0245725.
    PubMed     Abstract available


  116. ASADI M, Ahmadi N, Ahmadvand S, Jafari AA, et al
    Investigation of olfactory receptor family 51 subfamily j member 1 (OR51J1) gene susceptibility as a potential breast cancer-associated biomarker.
    PLoS One. 2021;16:e0246752.
    PubMed     Abstract available


  117. PHAM DX, Ho TH, Bui TD, Ho-Pham LT, et al
    Trends in breast cancer incidence in Ho Chi Minh City 1996-2015: A registry-based study.
    PLoS One. 2021;16:e0246800.
    PubMed     Abstract available


  118. JACKSON C, Freeman ALJ, Szlamka Z, Spiegelhalter DJ, et al
    The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis.
    PLoS One. 2021;16:e0246441.
    PubMed     Abstract available


  119. SANDOVAL RL, Leite ACR, Barbalho DM, Assad DX, et al
    Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    PLoS One. 2021;16:e0247363.
    PubMed     Abstract available


  120. NAFIE E, Lolarga J, Lam B, Guo J, et al
    Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
    PLoS One. 2021;16:e0247652.
    PubMed     Abstract available


  121. WANANDI SI, Limanto A, Yunita E, Syahrani RA, et al
    Correction: In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells.
    PLoS One. 2021;16:e0247694.
    PubMed     Abstract available


  122. AL-SALEH K, Salah T, Arafah M, Husain S, et al
    Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    PLoS One. 2021;16:e0247802.
    PubMed     Abstract available


  123. LUO HB, Liu YY, Wang CH, Qing HM, et al
    Radiomic features of axillary lymph nodes based on pharmacokinetic modeling DCE-MRI allow preoperative diagnosis of their metastatic status in breast cancer.
    PLoS One. 2021;16:e0247074.
    PubMed     Abstract available


  124. OLSEN KS, Holden M, Thalabard JC, Rasmussen Busund LT, et al
    Global blood gene expression profiles following a breast cancer diagnosis-Clinical follow-up in the NOWAC post-genome cohort.
    PLoS One. 2021;16:e0246650.
    PubMed     Abstract available


  125. RAHIMZADEH S, Burczynska B, Ahmadvand A, Sheidaei A, et al
    Geographical and socioeconomic inequalities in female breast cancer incidence and mortality in Iran: A Bayesian spatial analysis of registry data.
    PLoS One. 2021;16:e0248723.
    PubMed     Abstract available


  126. GRANQVIST V, Holmgren C, Larsson C
    Induction of interferon-beta and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells.
    PLoS One. 2021;16:e0248175.
    PubMed     Abstract available


  127. UMAMAHESWARAN G, Kadambari D, Muthuvel SK, Kumar NAN, et al
    Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
    PLoS One. 2021;16:e0247989.
    PubMed     Abstract available


  128. LOURO J, Roman M, Posso M, Vazquez I, et al
    Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening.
    PLoS One. 2021;16:e0248930.
    PubMed     Abstract available


  129. KOOP Y, Dobbe L, Maas AHEM, van Spronsen DJ, et al
    Oncology professionals' perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: A qualitative study.
    PLoS One. 2021;16:e0249067.
    PubMed     Abstract available


  130. GONG Z, Chen J, Wang J, Liu S, et al
    Differential methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry.
    PLoS One. 2021;16:e0249229.
    PubMed     Abstract available


  131. KLINGEN TA, Chen Y, Aas H, Wik E, et al
    Fibulin-2 expression associates with vascular invasion and patient survival in breast cancer.
    PLoS One. 2021;16:e0249767.
    PubMed     Abstract available


  132. MADUT A, Fuchsova V, Man H, Askar S, et al
    Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer.
    PLoS One. 2021;16:e0249099.
    PubMed     Abstract available


  133. AGUIRRE-CAMACHO A, Hidalgo B, Gonzalez-Cuevas G
    Fear of breast cancer among young Spanish women: Factor structure and psychometric properties of the Champion breast cancer fear scale.
    PLoS One. 2021;16:e0249562.
    PubMed     Abstract available


  134. LI J, Zhou Z, Dong J, Fu Y, et al
    Predicting breast cancer 5-year survival using machine learning: A systematic review.
    PLoS One. 2021;16:e0250370.
    PubMed     Abstract available


  135. CHAINITIKUN S, Espinosa Fernandez JR, Long JP, Iwase T, et al
    Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
    PLoS One. 2021;16:e0250057.
    PubMed     Abstract available


  136. NGUYEN HOANG AT, Hoe KL, Lee SJ
    CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
    PLoS One. 2021;16:e0246264.
    PubMed     Abstract available


  137. NISHIDA-FUKUDA H, Tokuhiro K, Ando Y, Matsushita H, et al
    Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines.
    PLoS One. 2021;16:e0249912.
    PubMed     Abstract available


  138. NERSISYAN S, Galatenko A, Galatenko V, Shkurnikov M, et al
    miRGTF-net: Integrative miRNA-gene-TF network analysis reveals key drivers of breast cancer recurrence.
    PLoS One. 2021;16:e0249424.
    PubMed     Abstract available


  139. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    PubMed     Abstract available


  140. HSIANG YP, Wang YT, Huang KS, Huang TY, et al
    Facile production of chlorophyllides using recombinant CrCLH1 and their cytotoxicity towards multidrug resistant breast cancer cell lines.
    PLoS One. 2021;16:e0250565.
    PubMed     Abstract available


  141. YANG C, He XF
    Evaluation of association studies and a systematic review and meta-analysis of CYP1A1 T3801C and A2455G polymorphisms in breast cancer risk.
    PLoS One. 2021;16:e0249632.
    PubMed     Abstract available


  142. AHMED SH, Espinoza-Sanchez NA, El-Damen A, Fahim SA, et al
    Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancer.
    PLoS One. 2021;16:e0250642.
    PubMed     Abstract available


  143. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    PubMed     Abstract available


  144. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    PubMed     Abstract available


  145. HOLTDIRK F, Mehnert A, Weiss M, Mayer J, et al
    Results of the Optimune trial: A randomized controlled trial evaluating a novel Internet intervention for breast cancer survivors.
    PLoS One. 2021;16:e0251276.
    PubMed     Abstract available


  146. VIJAYASARVESWARI V, Andrew AM, Jusoh M, Ahmad RB, et al
    Correction: Multi-stage feature selection (MSFS) algorithm for UWB-based early breast cancer size prediction.
    PLoS One. 2021;16:e0251679.
    PubMed     Abstract available


  147. ELOBAID Y, Aamir M, Grivna M, Suliman A, et al
    Breast cancer survival and its prognostic factors in the United Arab Emirates: A retrospective study.
    PLoS One. 2021;16:e0251118.
    PubMed     Abstract available


  148. PILLAI SG, Siddappa CM, Ma C, Snider J, et al
    A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patients.
    PLoS One. 2021;16:e0246139.
    PubMed     Abstract available


  149. SAKATA-MATSUZAWA M, Denda-Nagai K, Fujihira H, Noji M, et al
    Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens.
    PLoS One. 2021;16:e0250747.
    PubMed     Abstract available


  150. CHA YJ, Kim D, Bae SJ, Ahn SG, et al
    The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients.
    PLoS One. 2021;16:e0250986.
    PubMed     Abstract available


  151. RAGO M, Placidi L, Polsoni M, Rambaldi G, et al
    Evaluation of a generalized knowledge-based planning performance for VMAT irradiation of breast and locoregional lymph nodes-Internal mammary and/or supraclavicular regions.
    PLoS One. 2021;16:e0245305.
    PubMed     Abstract available


  152. YAMAMURO M, Asai Y, Hashimoto N, Yasuda N, et al
    The effect of breast density on the missed lesion rate in screening digital mammography determined using an adjustable-density breast phantom tailored to Japanese women.
    PLoS One. 2021;16:e0245060.
    PubMed     Abstract available


  153. LEE SB, Kim H, Kim J, Chung IY, et al
    Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy.
    PLoS One. 2021;16:e0251597.
    PubMed     Abstract available


  154. MA S, Shepard DS, Ritter GA, Martell RE, et al
    Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.
    PLoS One. 2021;16:e0250967.
    PubMed     Abstract available


  155. VELAZQUEZ FN, Zhang L, Viscardi V, Trocchia C, et al
    Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer.
    PLoS One. 2021;16:e0252311.
    PubMed     Abstract available


  156. KIM HS, Kim MG, Min KW, Jung US, et al
    High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
    PLoS One. 2021;16:e0252052.
    PubMed     Abstract available


  157. NG DY, Tudor Car L, Ng MJM, Lu J, et al
    Identifying barriers to early presentation in patients with locally advanced breast cancer (LABC) in Northern Singapore: Qualitative study.
    PLoS One. 2021;16:e0252008.
    PubMed     Abstract available


  158. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
    PLoS One. 2021;16:e0253176.
    PubMed     Abstract available


  159. LEE J, Kang BJ, Kim SH
    Usefulness of postoperative surveillance MR for women after breast-conservation therapy: Focusing on MR features of early and late recurrent breast cancer.
    PLoS One. 2021;16:e0252476.
    PubMed     Abstract available


  160. AKLILU S, Bain C, Bansil P, de Sanjose S, et al
    Evaluation of diagnostic ultrasound use in a breast cancer detection strategy in Northern Peru.
    PLoS One. 2021;16:e0252902.
    PubMed     Abstract available


  161. PODUVAL D, Sichmanova Z, Straume AH, Lonning PE, et al
    Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer.
    PLoS One. 2021;16:e0253361.
    PubMed     Abstract available


  162. KANG Z, Chen S, Shi L, He Y, et al
    Predictors of heart and lung dose in left-sided breast cancer treated with VMAT relative to 3D-CRT: A retrospective study.
    PLoS One. 2021;16:e0252552.
    PubMed     Abstract available


  163. WATANABE T, Oba T, Tanimoto K, Shibata T, et al
    Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    PLoS One. 2021;16:e0252822.
    PubMed     Abstract available


  164. AL-KEILANI MS, Elstaty RI, Alqudah MA, Alkhateeb AM, et al
    Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index.
    PLoS One. 2021;16:e0252616.
    PubMed     Abstract available


  165. ZHU L, Cui K, Weng L, Yu P, et al
    A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells.
    PLoS One. 2021;16:e0249174.
    PubMed     Abstract available


  166. DING H, Buzzard GW, Huang S, Sehorn MG, et al
    MICA-G129R: A bifunctional fusion protein increases PRLR-positive breast cancer cell death in co-culture with natural killer cells.
    PLoS One. 2021;16:e0252662.
    PubMed     Abstract available



  167. Retraction: AIB1 Cooperates with ERalpha to Promote Epithelial Mesenchymal Transition in Breast Cancer through SNAI1 Activation.
    PLoS One. 2021;16:e0252791.
    PubMed    


  168. OSEI-AFRIYIE S, Addae AK, Oppong S, Amu H, et al
    Breast cancer awareness, risk factors and screening practices among future health professionals in Ghana: A cross-sectional study.
    PLoS One. 2021;16:e0253373.
    PubMed     Abstract available


  169. HSU SN, Hui EWE, Liu M, Wu D, et al
    Revealing nuclear receptor hub modules from Basal-like breast cancer expression networks.
    PLoS One. 2021;16:e0252901.
    PubMed     Abstract available


  170. SALAS M, Henderson M, Sundararajan M, Tu N, et al
    Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
    PLoS One. 2021;16:e0252925.
    PubMed     Abstract available


  171. ALMUHTASEB MIA, Alby F, Zucchermaglio C, Fatigante M, et al
    Social support for breast cancer patients in the occupied Palestinian territory.
    PLoS One. 2021;16:e0252608.
    PubMed     Abstract available


  172. WIELEMA M, Sijens PE, Dijkstra H, De Bock GH, et al
    Diffusion weighted imaging of the breast: Performance of standardized breast tumor tissue selection methods in clinical decision making.
    PLoS One. 2021;16:e0245930.
    PubMed     Abstract available


  173. VIVES N, Farre A, Ibanez-Sanz G, Vidal C, et al
    Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol.
    PLoS One. 2021;16:e0245806.
    PubMed     Abstract available


  174. LI Z, Zhang J, Zou W, Xu Q, et al
    The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China.
    PLoS One. 2021;16:e0254267.
    PubMed     Abstract available


  175. KENNEY J, Ndoye A, Lamar JM, DiPersio CM, et al
    Comparative use of CRISPR and RNAi to modulate integrin alpha3beta1 in triple negative breast cancer cells reveals that some pro-invasive/pro-metastatic alpha3beta1 functions are independent of global regulation of the transcriptome.
    PLoS One. 2021;16:e0254714.
    PubMed     Abstract available


  176. YANG J, Virostko J, Hormuth DA 2nd, Liu J, et al
    An experimental-mathematical approach to predict tumor cell growth as a function of glucose availability in breast cancer cell lines.
    PLoS One. 2021;16:e0240765.
    PubMed     Abstract available


  177. KIM H, Kwon S, Son SM, Jeong E, et al
    Tailored approach to the choice of long-term vascular access in breast cancer patients.
    PLoS One. 2021;16:e0255004.
    PubMed     Abstract available


  178. LOTHONG M, Sakares W, Rojsitthisak P, Tanikawa C, et al
    Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway.
    PLoS One. 2021;16:e0255179.
    PubMed     Abstract available


  179. RATH S, Elamarthi P, Parab P, Gulia S, et al
    Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
    PLoS One. 2021;16:e0253722.
    PubMed     Abstract available


  180. KING L, Flaus A, Holian E, Golden A, et al
    Survival outcomes are associated with genomic instability in luminal breast cancers.
    PLoS One. 2021;16:e0245042.
    PubMed     Abstract available


  181. KIM JJ, Liang W, Kang CC, Pegram MD, et al
    Single-cell immunoblotting resolves estrogen receptor-alpha isoforms in breast cancer.
    PLoS One. 2021;16:e0254783.
    PubMed     Abstract available


  182. AHMED F, Adnan M, Malik A, Tariq S, et al
    Perception of breast cancer risk factors: Dysregulation of TGF-beta/miRNA axis in Pakistani females.
    PLoS One. 2021;16:e0255243.
    PubMed     Abstract available


  183. DANTAS DE ARAUJO SANTOS CAMARG, Dos Santos J, Simoes TC, Carvalho JBL, et al
    Mortality due to breast cancer in a region of high socioeconomic vulnerability in Brazil: Analysis of the effect of age-period and cohort.
    PLoS One. 2021;16:e0255935.
    PubMed     Abstract available


  184. NORDIN FJ, Pearanpan L, Chan KM, Kumolosasi E, et al
    Immunomodulatory potential of Clinacanthus nutans extracts in the co-culture of triple-negative breast cancer cells, MDA-MB-231, and THP-1 macrophages.
    PLoS One. 2021;16:e0256012.
    PubMed     Abstract available


  185. ASTARITA EM, Maloney SM, Hoover CA, Berkeley BJ, et al
    Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells.
    PLoS One. 2021;16:e0255738.
    PubMed     Abstract available


  186. SUN Z, Nyberg R, Wu Y, Bernard B, et al
    Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
    PLoS One. 2021;16:e0247238.
    PubMed     Abstract available


  187. PORCIELLO G, Montagnese C, Crispo A, Grimaldi M, et al
    Correction: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial.
    PLoS One. 2021;16:e0256944.
    PubMed     Abstract available


  188. HEENAYE-MAMODE KHAN M, Boodoo-Jahangeer N, Dullull W, Nathire S, et al
    Multi- class classification of breast cancer abnormalities using Deep Convolutional Neural Network (CNN).
    PLoS One. 2021;16:e0256500.
    PubMed     Abstract available


  189. ARNEJA J, Brooks JD
    The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada.
    PLoS One. 2021;16:e0256536.
    PubMed     Abstract available


  190. AHN HS, Kim SH, Kim JY, Park CS, et al
    Image quality and diagnostic value of diffusion-weighted breast magnetic resonance imaging: Comparison of acquired and computed images.
    PLoS One. 2021;16:e0247379.
    PubMed     Abstract available


  191. XIA LY, Xu WY, Hu QL
    The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: A population-based study.
    PLoS One. 2021;16:e0256893.
    PubMed     Abstract available


  192. JANK P, Gehlhaar C, Lederer B, Fontanella C, et al
    Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
    PLoS One. 2021;16:e0257142.
    PubMed     Abstract available


  193. WOO J, Kim JB, Cho T, Yoo EH, et al
    Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.
    PLoS One. 2021;16:e0257298.
    PubMed     Abstract available


  194. ALAM NE, Islam MS, Ullah H, Molla MT, et al
    Evaluation of knowledge, awareness and attitudes towards breast cancer risk factors and early detection among females in Bangladesh: A hospital based cross-sectional study.
    PLoS One. 2021;16:e0257271.
    PubMed     Abstract available


  195. TESHOME B, Trabitzsch J, Afework T, Addissie A, et al
    Perceived barriers to timely treatment initiation and social support status among women with breast cancer in Ethiopia.
    PLoS One. 2021;16:e0257163.
    PubMed     Abstract available


  196. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
    PLoS One. 2021;16:e0257860.
    PubMed     Abstract available


  197. MEKONEN S, Ibrahim M, Astatkie H, Abreha A, et al
    Exposure to organochlorine pesticides as a predictor to breast cancer: A case-control study among Ethiopian women.
    PLoS One. 2021;16:e0257704.
    PubMed     Abstract available


  198. CASELLI E, Pelliccia C, Teti V, Bellezza G, et al
    Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
    PLoS One. 2021;16:e0255580.
    PubMed     Abstract available


  199. CIRIA-SUAREZ L, Jimenez-Fonseca P, Palacin-Lois M, Antonanzas-Basa M, et al
    Breast cancer patient experiences through a journey map: A qualitative study.
    PLoS One. 2021;16:e0257680.
    PubMed     Abstract available


  200. OLAYA-GALAN NN, Salas-Cardenas SP, Rodriguez-Sarmiento JL, Ibanez-Pinilla M, et al
    Risk factor for breast cancer development under exposure to bovine leukemia virus in Colombian women: A case-control study.
    PLoS One. 2021;16:e0257492.
    PubMed     Abstract available


  201. HADJIPANTELI A, Polyviou P, Kyriakopoulos I, Genagritis M, et al
    Comparison of two-view versus single-view digital breast tomosynthesis and 2D-mammography in breast cancer surveillance imaging.
    PLoS One. 2021;16:e0256514.
    PubMed     Abstract available


  202. SANI L, Vispa A, Loretoni R, Duranti M, et al
    Breast lesion detection through MammoWave device: Empirical detection capability assessment of microwave images' parameters.
    PLoS One. 2021;16:e0250005.
    PubMed     Abstract available


  203. JARM K, Kadivec M, Sval C, Hertl K, et al
    Quality assured implementation of the Slovenian breast cancer screening programme.
    PLoS One. 2021;16:e0258343.
    PubMed     Abstract available


  204. SAKSORNCHAI K, Jaruthien T, Nantavithya C, Shotelersuk K, et al
    Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: A prospective study.
    PLoS One. 2021;16:e0258186.
    PubMed     Abstract available


  205. GARCIA MT, Mota BS, Cardoso N, Martimbianco ALC, et al
    Accuracy of frozen section in intraoperative margin assessment for breast-conserving surgery: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0248768.
    PubMed     Abstract available


  206. XIE Y, Guo B, Zhang R
    Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation.
    PLoS One. 2021;16:e0248220.
    PubMed     Abstract available


  207. MOHAMED RI, Bargal SA, Mekawy AS, El-Shiekh I, et al
    The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine.
    PLoS One. 2021;16:e0247837.
    PubMed     Abstract available


  208. PARK JH, Jung YS, Kim JY, Bae SH, et al
    Determinants of quality of life in women immediately following the completion of primary treatment of breast cancer: A cross-sectional study.
    PLoS One. 2021;16:e0258447.
    PubMed     Abstract available


  209. STONE JK, Vukadin L, Ahn EE
    eNEMAL, an enhancer RNA transcribed from a distal MALAT1 enhancer, promotes NEAT1 long isoform expression.
    PLoS One. 2021;16:e0251515.
    PubMed     Abstract available


  210. ZOELLER JJ, Press MF, Selfors LM, Dering J, et al
    Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
    PLoS One. 2021;16:e0251163.
    PubMed     Abstract available


  211. BLASI MA, Maceroni M, Caputo CG, Sammarco MG, et al
    Clinical and ultrasonographic features of choroidal metastases based on primary cancer site: Long-term experience in a single center.
    PLoS One. 2021;16:e0249210.
    PubMed     Abstract available


  212. JAMES JE, Riddle L, Koenig BA, Joseph G, et al
    The limits of personalization in precision medicine: Polygenic risk scores and racial categorization in a precision breast cancer screening trial.
    PLoS One. 2021;16:e0258571.
    PubMed     Abstract available


  213. OPOKU F, Bedu-Addo K, Titiloye NA, Atta Manu E, et al
    Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana.
    PLoS One. 2021;16:e0258543.
    PubMed     Abstract available


  214. JENSEN MD, Hansen KM, Siersma V, Brodersen J, et al
    Using a Deliberative Poll on breast cancer screening to assess and improve the decision quality of laypeople.
    PLoS One. 2021;16:e0258869.
    PubMed     Abstract available


  215. BROCK EJ, Jackson RM, Boerner JL, Li Q, et al
    Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma.
    PLoS One. 2021;16:e0252314.
    PubMed     Abstract available


  216. AGODIRIN O, Olatoke S, Rahman G, Kolawole O, et al
    Determinants of late detection and advanced-stage diagnosis of breast cancer in Nigeria.
    PLoS One. 2021;16:e0256847.
    PubMed     Abstract available


  217. MARES AG, Pacassoni G, Marti JS, Pujals S, et al
    Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology.
    PLoS One. 2021;16:e0251821.
    PubMed     Abstract available


  218. AMIRFALLAH A, Knutsdottir H, Arason A, Hilmarsdottir B, et al
    Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways.
    PLoS One. 2021;16:e0260327.
    PubMed     Abstract available


  219. QIU P, Guo Q, Yao Q, Chen J, et al
    Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
    PLoS One. 2021;16:e0254283.
    PubMed     Abstract available


  220. HANSEN JA, Naghavi-Behzad M, Gerke O, Baun C, et al
    Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
    PLoS One. 2021;16:e0260066.
    PubMed     Abstract available


  221. WU WP, Chen CY, Lee CW, Wu HK, et al
    Impact of pre-operative breast magnetic resonance imaging on contralateral synchronous and metachronous breast cancer detection-A case control comparison study with 1468 primary operable breast cancer patients with mean follow-up of 102 months.
    PLoS One. 2021;16:e0260093.
    PubMed     Abstract available


  222. DARGA EP, Dolce EM, Fang F, Kidwell KM, et al
    PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
    PLoS One. 2021;16:e0260124.
    PubMed     Abstract available


  223. MEKONEN S, Ibrahim M, Astatkie H, Abreha A, et al
    Correction: Exposure to organochlorine pesticides as a predictor to breast cancer: A case-control study among Ethiopian women.
    PLoS One. 2021;16:e0260106.
    PubMed     Abstract available


  224. EZZALFANI M, Porcher R, Savignoni A, Delaloge S, et al
    Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project.
    PLoS One. 2021;16:e0255017.
    PubMed     Abstract available


  225. KAGAYA Y, Arikawa M, Sekiyama T, Mitsuwa H, et al
    The concept of "whole perforator system" in the lateral thoracic region for latissimus dorsi muscle-preserving large flaps: An anatomical study and case series.
    PLoS One. 2021;16:e0256962.
    PubMed     Abstract available


  226. PRATOOMCHART C, Klunklin P, Wanwilairat S, Nobnop W, et al
    The advantages of abdominal compression with shallow breathing during left-sided postmastectomy radiotherapy by Helical TomoTherapy.
    PLoS One. 2021;16:e0254934.
    PubMed     Abstract available


  227. HE Q, Cheng G, Ju H
    BCDnet: Parallel heterogeneous eight-class classification model of breast pathology.
    PLoS One. 2021;16:e0253764.
    PubMed     Abstract available


  228. GUO Y, Duan X, Wang C, Guo H, et al
    Segmentation and recognition of breast ultrasound images based on an expanded U-Net.
    PLoS One. 2021;16:e0253202.
    PubMed     Abstract available


  229. GHANBARI S, Salimi A, Rahmani S, Nafissi N, et al
    miR-361-5p as a promising qRT-PCR internal control for tumor and normal breast tissues.
    PLoS One. 2021;16:e0253009.
    PubMed     Abstract available


  230. HARTMANN B, Muller M, Seyler L, Bauerle T, et al
    Feasibility of deuterium magnetic resonance spectroscopy of 3-O-Methylglucose at 7 Tesla.
    PLoS One. 2021;16:e0252935.
    PubMed     Abstract available


  231. EASLEY TO, Ren Z, Kim B, Karczmar GS, et al
    Enhancement-constrained acceleration: A robust reconstruction framework in breast DCE-MRI.
    PLoS One. 2021;16:e0258621.
    PubMed     Abstract available


  232. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available


  233. BRUCKMANN NM, Kirchner J, Morawitz J, Umutlu L, et al
    Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    PLoS One. 2021;16:e0260804.
    PubMed     Abstract available


  234. ADEYEMI OJ, Gill TL, Paul R, Huber LB, et al
    Evaluating the association of self-reported psychological distress and self-rated health on survival times among women with breast cancer in the U.S.
    PLoS One. 2021;16:e0260481.
    PubMed     Abstract available


  235. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed     Abstract available


  236. ALACHRAM H, Chereda H, Beissbarth T, Wingender E, et al
    Text mining-based word representations for biomedical data analysis and protein-protein interaction networks in machine learning tasks.
    PLoS One. 2021;16:e0258623.
    PubMed     Abstract available


  237. SHAMMOUT ODA, Ashmawy NS, Shakartalla SB, Altaie AM, et al
    Comparative sphingolipidomic analysis reveals significant differences between doxorubicin-sensitive and -resistance MCF-7 cells.
    PLoS One. 2021;16:e0258363.
    PubMed     Abstract available


  238. KEETILE M, Ndlovu K, Letamo G, Disang M, et al
    Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana.
    PLoS One. 2021;16:e0255581.
    PubMed     Abstract available


  239. LENG X, Huang G, Li S, Yao M, et al
    Correlation of breast cancer microcirculation construction with tumor stem cells (CSCs) and epithelial-mesenchymal transition (EMT) based on contrast-enhanced ultrasound (CEUS).
    PLoS One. 2021;16:e0261138.
    PubMed     Abstract available


  240. SON Y, Han K, Lee YS, Yu J, et al
    Privacy-preserving breast cancer recurrence prediction based on homomorphic encryption and secure two party computation.
    PLoS One. 2021;16:e0260681.
    PubMed     Abstract available


  241. POLITI MC, Saunders CH, Grabinski VF, Yen RW, et al
    An absence of equipoise: Examining surgeons' decision talk during encounters with women considering breast cancer surgery.
    PLoS One. 2021;16:e0260704.
    PubMed     Abstract available


  242. ZHOU Z, Li J, Wang H, Luan Z, et al
    Upper limb rehabilitation system based on virtual reality for breast cancer patients: Development and usability study.
    PLoS One. 2021;16:e0261220.
    PubMed     Abstract available


  243. FOMITCHEVA-KHARTCHENKO A, Rapsomaniki MA, Sobottka B, Schraml P, et al
    Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity.
    PLoS One. 2021;16:e0259332.
    PubMed     Abstract available


  244. ZIMMERMANN RC, Sardiu ME, Manton CA, Miah MS, et al
    Perturbation of BRMS1 interactome reveals pathways that impact metastasis.
    PLoS One. 2021;16:e0259128.
    PubMed     Abstract available


  245. SUN Y, Ji Y
    AAWS-Net: Anatomy-aware weakly-supervised learning network for breast mass segmentation.
    PLoS One. 2021;16:e0256830.
    PubMed     Abstract available


  246. BREDNO J, Lipson J, Venn O, Aravanis AM, et al
    Clinical correlates of circulating cell-free DNA tumor fraction.
    PLoS One. 2021;16:e0256436.
    PubMed     Abstract available


  247. HE X, Anthony DC, Catoni Z, Cao W, et al
    Pulmonary tumor embolism: A retrospective study over a 30-year period.
    PLoS One. 2021;16:e0255917.
    PubMed     Abstract available


  248. LIN KH, Hsu HM, Hsu KF, Chu CH, et al
    Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study.
    PLoS One. 2021;16:e0261258.
    PubMed     Abstract available


  249. HU Y, Zou D
    Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.
    PLoS One. 2021;16:e0260811.
    PubMed     Abstract available


  250. AWODUTIRE PO, Balogun OS, Olapade AK, Nduka EC, et al
    The modified beta transmuted family of distributions with applications using the exponential distribution.
    PLoS One. 2021;16:e0258512.
    PubMed     Abstract available


  251. CHANG YY, Lin HJ, Hsiao LC, Lin YF, et al
    Reduction of breast tumor drug resistance by 2,3,5,4'-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect.
    PLoS One. 2021;16:e0260533.
    PubMed     Abstract available


  252. TANAKA M, Tanaka T, Takamatsu M, Shibue C, et al
    Effects of the Kampo medicine Yokukansan for perioperative anxiety and postoperative pain in women undergoing breast surgery: A randomized, controlled trial.
    PLoS One. 2021;16:e0260524.
    PubMed     Abstract available


  253. KAUR P, Nagar S, Bhagwat M, Uddin M, et al
    Activated heme synthesis regulates glycolysis and oxidative metabolism in breast and ovarian cancer cells.
    PLoS One. 2021;16:e0260400.
    PubMed     Abstract available


  254. ZHANG X, Kschischo M
    MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes.
    PLoS One. 2021;16:e0261183.
    PubMed     Abstract available


  255. OZGENCIL M, Barwell J, Tischkowitz M, Izatt L, et al
    Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance.
    PLoS One. 2021;16:e0260852.
    PubMed     Abstract available


  256. HIRAMOTO S, Asano H, Miyamoto T, Takegami M, et al
    Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
    PLoS One. 2021;16:e0261473.
    PubMed     Abstract available


    January 2020
  257. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed     Abstract available


  258. HARATI R, Hafezi S, Mabondzo A, Tlili A, et al
    Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells.
    PLoS One. 2020;15:e0239292.
    PubMed     Abstract available


  259. GUO A, Drake BF, Khan YM, Langabeer Ii JR, et al
    Time-series cardiovascular risk factors and receipt of screening for breast, cervical, and colon cancer: The Guideline Advantage.
    PLoS One. 2020;15:e0236836.
    PubMed     Abstract available


  260. ROSEN S, Brisson BK, Durham AC, Munroe CM, et al
    Intratumoral collagen signatures predict clinical outcomes in feline mammary carcinoma.
    PLoS One. 2020;15:e0236516.
    PubMed     Abstract available


  261. LELLUPITIYAGE DON SS, Robertson KL, Lin HH, Labriola C, et al
    Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner.
    PLoS One. 2020;15:e0236315.
    PubMed     Abstract available


  262. PORCIELLO G, Montagnese C, Crispo A, Grimaldi M, et al
    Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial.
    PLoS One. 2020;15:e0239803.
    PubMed     Abstract available



  263. Retraction: Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer.
    PLoS One. 2020;15:e0240575.
    PubMed    



  264. Retraction: Inhibition of endothelial cell proliferation and tumor angiogenesis by up-regulating NDRG2 expression in breast cancer cells.
    PLoS One. 2020;15:e0240574.
    PubMed    


  265. SOLIMAN SSM, Alhamidi TB, Abdin S, Almehdi AM, et al
    Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites.
    PLoS One. 2020;15:e0240156.
    PubMed     Abstract available


  266. DELARMELINA E, Buzelin MA, Souza BS, Souto FM, et al
    High positivity values for bovine leukemia virus in human breast cancer cases from Minas Gerais, Brazil.
    PLoS One. 2020;15:e0239745.
    PubMed     Abstract available


  267. SONG JH, Eum DY, Park SY, Jin YH, et al
    Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells.
    PLoS One. 2020;15:e0240533.
    PubMed     Abstract available


  268. RODRIGUEZ NM, Casanova F, Pages G, Claure L, et al
    Community-based participatory design of a community health worker breast cancer training intervention for South Florida Latinx farmworkers.
    PLoS One. 2020;15:e0240827.
    PubMed     Abstract available



  269. Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
    PLoS One. 2020;15:e0241089.
    PubMed     Abstract available


  270. MOSAYEBI A, Mojaradi B, Bonyadi Naeini A, Khodadad Hosseini SH, et al
    Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer.
    PLoS One. 2020;15:e0237658.
    PubMed     Abstract available


  271. PARK SH, Jeong YM, Lee HY, Kim EY, et al
    Opportunistic use of chest CT for screening osteoporosis and predicting the risk of incidental fracture in breast cancer patients: A retrospective longitudinal study.
    PLoS One. 2020;15:e0240084.
    PubMed     Abstract available


  272. CHA YJ, Koo JS
    Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
    PLoS One. 2020;15:e0238466.
    PubMed     Abstract available


  273. SHARMA D, Cartar H, Law N, Giles A, et al
    Optimization of microbubble enhancement of hyperthermia for cancer therapy in an in vivo breast tumour model.
    PLoS One. 2020;15:e0237372.
    PubMed     Abstract available


  274. ZHANG C, Zhao J, Niu J, Li D, et al
    New convolutional neural network model for screening and diagnosis of mammograms.
    PLoS One. 2020;15:e0237674.
    PubMed     Abstract available


  275. YEASMEEN T, Kelaher M, Brotherton JML, Malloy MJ, et al
    Understanding the participation of breast screening among women born in predominantly Muslim countries living in Victoria, Australia from record-linkage data.
    PLoS One. 2020;15:e0237341.
    PubMed     Abstract available


  276. DAHMANI Z, Addou-Klouche L, Gizard F, Dahou S, et al
    Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity.
    PLoS One. 2020;15:e0240982.
    PubMed     Abstract available


  277. LEE SB, Gwark SC, Kang CM, Sohn G, et al
    The effects of poloxamer and sodium alginate mixture (Guardix-SG(R)) on range of motion after axillary lymph node dissection: A single-center, prospective, randomized, double-blind pilot study.
    PLoS One. 2020;15:e0238284.
    PubMed     Abstract available


  278. BAIO G, Fabbi M, Cilli M, Rosa F, et al
    Manganese-enhanced MRI (MEMRI) in breast and prostate cancers: Preliminary results exploring the potential role of calcium receptors.
    PLoS One. 2020;15:e0224414.
    PubMed     Abstract available


  279. ESPANOL AJ, Salem A, Di Bari M, Cristofaro I, et al
    The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
    PLoS One. 2020;15:e0226450.
    PubMed     Abstract available


  280. BARTLETT JMS, Bayani J, Kornaga EN, Danaher P, et al
    Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.
    PLoS One. 2020;15:e0238593.
    PubMed     Abstract available


  281. TRACY JK, Adetunji F, Al Kibria GM, Swanberg JE, et al
    Cancer-work management: Hourly and salaried wage women's experiences managing the cancer-work interface following new breast cancer diagnosis.
    PLoS One. 2020;15:e0241795.
    PubMed     Abstract available


  282. BODILY WR, Shirts BH, Walsh T, Gulsuner S, et al
    Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    PLoS One. 2020;15:e0239197.
    PubMed     Abstract available


  283. LUO CY, Natividad RJ, Lalli ML, Asthagiri AR, et al
    Multivariate relationships among nucleus and Golgi properties during fibrillar migration are robust to and unchanged by epithelial-to-mesenchymal transition.
    PLoS One. 2020;15:e0239188.
    PubMed     Abstract available


  284. HUANG JS, Pan HB, Yang TL, Hung BH, et al
    Kinetic patterns of benign and malignant breast lesions on contrast enhanced digital mammogram.
    PLoS One. 2020;15:e0239271.
    PubMed     Abstract available


  285. CUI P, Chen Y, Waili N, Li Y, et al
    Associations of serum C-peptide and insulin-like growth factor binding proteins-3 with breast cancer deaths.
    PLoS One. 2020;15:e0242310.
    PubMed     Abstract available


  286. CRESPO J, Sun H, Wu J, Ding QQ, et al
    Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    PLoS One. 2020;15:e0241775.
    PubMed     Abstract available


  287. BAJAJ R, Tripathi R, Sridhar TS, Korlimarla A, et al
    Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer.
    PLoS One. 2020;15:e0242190.
    PubMed     Abstract available


  288. MO W, Ding Y, Zhao S, Zou D, et al
    Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis.
    PLoS One. 2020;15:e0241924.
    PubMed     Abstract available


  289. LIN H, Wu Y, Liang G, Chen L, et al
    Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery.
    PLoS One. 2020;15:e0242155.
    PubMed     Abstract available


  290. CHANG TC, Matossian MD, Elliott S, Burks HE, et al
    Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
    PLoS One. 2020;15:e0226464.
    PubMed     Abstract available


  291. BERA A, Subramanian M, Karaian J, Eklund M, et al
    Functional role of vitronectin in breast cancer.
    PLoS One. 2020;15:e0242141.
    PubMed     Abstract available


  292. WANANDI SI, Limanto A, Yunita E, Syahrani RA, et al
    In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells.
    PLoS One. 2020;15:e0240020.
    PubMed     Abstract available


  293. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study.
    PLoS One. 2020;15:e0242563.
    PubMed     Abstract available


  294. CHIANG ZC, Chiu YK, Lee CC, Hsu NS, et al
    Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells.
    PLoS One. 2020;15:e0239813.
    PubMed     Abstract available


  295. MATHEWS PM, Robinson SA, Gire A, Baer AN, et al
    Extraglandular ocular involvement and morbidity and mortality in primary Sjogren's Syndrome.
    PLoS One. 2020;15:e0239769.
    PubMed     Abstract available


  296. AFRIN K, Iquebal AS, Karimi M, Souris A, et al
    Directionally dependent multi-view clustering using copula model.
    PLoS One. 2020;15:e0238996.
    PubMed     Abstract available


  297. TESFAW A, Alebachew W, Tiruneh M
    Why women with breast cancer presented late to health care facility in North-west Ethiopia? A qualitative study.
    PLoS One. 2020;15:e0243551.
    PubMed     Abstract available


  298. CARTER KJ, Castro F, Morcos RN
    A method for evaluating breast cancer screening strategies using screen-preventable loss of life.
    PLoS One. 2020;15:e0243113.
    PubMed     Abstract available


  299. ZOU Y, Fineberg S, Pearlman A, Feinman RD, et al
    The effect of a ketogenic diet and synergy with rapamycin in a mouse model of breast cancer.
    PLoS One. 2020;15:e0233662.
    PubMed     Abstract available


  300. DE MEULENAERE V, Descamps B, De Wever O, Vanhove C, et al
    In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis.
    PLoS One. 2020;15:e0243156.
    PubMed     Abstract available


  301. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    PubMed     Abstract available


  302. SHI Y, Gong W, Gong X, Wang P, et al
    Genome-wide DNA methylation analysis of breast cancer MCF-7 / Taxol cells with MeDIP-Seq.
    PLoS One. 2020;15:e0241515.
    PubMed     Abstract available


  303. MAO Y, Zhao Y, Zhang Y, Yang H, et al
    In-depth characterization and comparison of the N-glycosylated proteome of two-dimensional- and three-dimensional-cultured breast cancer cells and xenografted tumors.
    PLoS One. 2020;15:e0243789.
    PubMed     Abstract available


  304. NAGHIBI L, Yazdani M, Momtazi-Borojeni AA, Razazan A, et al
    Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
    PLoS One. 2020;15:e0243550.
    PubMed     Abstract available


  305. DE LA CRUZ-KU G, Chambergo-Michilot D, Torres-Roman JS, Rebaza P, et al
    Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer.
    PLoS One. 2020;15:e0243447.
    PubMed     Abstract available


  306. BAR-SELA G, Cohen I, Avisar A, Loven D, et al
    Circulating blood extracellular vesicles as a tool to assess endothelial injury and chemotherapy toxicity in adjuvant cancer patients.
    PLoS One. 2020;15:e0240994.
    PubMed     Abstract available


  307. MOODLEY J, Constant D, Mwaka AD, Scott SE, et al
    Mapping awareness of breast and cervical cancer risk factors, symptoms and lay beliefs in Uganda and South Africa.
    PLoS One. 2020;15:e0240788.
    PubMed     Abstract available


  308. MOGAKA JJO, Chimbari MJ
    The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    PLoS One. 2020;15:e0240585.
    PubMed     Abstract available


  309. LI X, Plataniotis KN
    How much off-the-shelf knowledge is transferable from natural images to pathology images?
    PLoS One. 2020;15:e0240530.
    PubMed     Abstract available


  310. CIRIA-SUAREZ L, Jimenez-Fonseca P, Palacin-Lois M, Antonanzas-Basa M, et al
    Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol.
    PLoS One. 2020;15:e0244355.
    PubMed     Abstract available


  311. WANG L, Wang W, Zeng S, Zheng H, et al
    Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients.
    PLoS One. 2020;15:e0244693.
    PubMed     Abstract available


  312. ZABALLA O, Perez A, Gomez Inhiesto E, Acaiturri Ayesta T, et al
    Identifying common treatments from Electronic Health Records with missing information. An application to breast cancer.
    PLoS One. 2020;15:e0244004.
    PubMed     Abstract available


  313. MOODLEY J, Williams P, Gohla G, Major P, et al
    Variation in breast cancer grading in 1,636 resections assessed using control charts and in silico kappa.
    PLoS One. 2020;15:e0242656.
    PubMed     Abstract available


  314. MEKONNEN BD
    Breast self-examination practice and associated factors among female healthcare workers in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0241961.
    PubMed     Abstract available


  315. WINNARD PT JR, Vesuna F, Muthukumar S, Raman V, et al
    Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity.
    PLoS One. 2020;15:e0242384.
    PubMed     Abstract available


  316. DE LOS CAMPOS G, Pook T, Gonzalez-Reymundez A, Simianer H, et al
    ANOVA-HD: Analysis of variance when both input and output layers are high-dimensional.
    PLoS One. 2020;15:e0243251.
    PubMed     Abstract available


  317. OSAPOETRA LO, Chan W, Tran W, Kolios MC, et al
    Comparison of methods for texture analysis of QUS parametric images in the characterization of breast lesions.
    PLoS One. 2020;15:e0244965.
    PubMed     Abstract available


  318. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
    Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
    PLoS One. 2020;15:e0244644.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: